ATRX and cancer: The frequency of tumors lacking detectable hTERT expression and mutations of ATRX/DAXX reached up to 70–80% in some cancer types like thyroid carcinoma (79.1%), kidney renal papillary cell carcinoma (70.2%), kidney cromophobe carcinoma (80%) [25] (Table 1).